PMCB

3.97512.83%
HH

Hans-Peter Hammes

Member of Medical & Scientific Advisory Board and Consultant

Dr. Hans-Peter Hammes, M.D., has been Consultant at PharmaCyte Biotech, Inc. since November 19, 2015. Dr Hammes is a Professor of Internal Medicine and Endocrinology at the University Medical Center Mannheim, University of Heidelberg, Germany. Dr Hammes held several positions in the field of diabetes, with emphasis on the biochemistry of diabetic complications, diabetic retinopathy, angiogenesis and predictors of vascular complication from diabetes. Dr Hammes is recognized worldwide for his work on the retinopathy (damage to the eyes) that can result from diabetes. Dr Hammes has been a Member of Medical and Scientific Advisory Board at PharmaCyte Biotech, Inc. since November 19, 2015. Dr Hammes was trained in diabetes by the one of the world’s most recognized authorities on the treatment of diabetes, Dr Konrad Federlin, at the University of Giessen, Germany. In 1996, Dr Hammes was named “Diabetologist” by the German Diabetes Association. Dr Hammes is one of Europe’s leading authorities in all aspects of diabetes and is well versed on the types of studies that needed to develop an effective treatment for the disease. Dr Hammes is recognized internationally as a preeminent figure in the treatment of diabetes and its complications. Dr Hammes is a Member of PharmaCyte’s international Diabetes Consortium. Dr Hammes is a Member of several professional organizations, including the German Society of Internal Medicine, the German Society of Endocrinology and the European Association for the Study of Diabetes (EASD). Dr Hammes was this year’s recipient of the prestigious Camillo Golgi Prize awarded by EASD at its annual meeting. He has co-authored over 200 scientific articles and books involving diabetes. Dr Hammes received his Medical Degree from Westfälische Wilhelm-University in Münster, Germany. He graduated in 1980.

Positions